In line for 50,000 type 1 diabetics: The “artificial pancreas” system has entered the health basket

In line for 50,000 type 1 diabetics: The "artificial pancreas" system has entered the health basket

In a row of life for 50,000 type 1 diabetics living in Israel today, and especially for the 5,000 children among them: After many years of waiting, Medtronic’s “artificial pancreas” system, which includes technology developed at the Schneider Center for Pediatrics in collaboration with DreaMed Diabetes, entered last week To the Health Basket 2022.

Diabetes requires constant monitoring of diet and blood sugar, and requires patients to inject insulin into the body around the clock to compensate for pancreatic dysfunction. Insulin-dependent diabetes is a growing global problem affecting more than 90 million people worldwide, and in order to prevent serious complications ongoing monitoring of blood sugar is critical. Despite advances in insulin therapy and glucose monitoring devices, most patients do not reach the glucose targets set for them and are prone to chronic and costly complications.

The artificial pancreatic system includes a sensor that is inserted into the subcutaneous tissue and monitors the sugar level, and a pump that releases insulin. The sensor and pump are connected to algorithms, the “brain”, which includes the technology developed at Schneider.

The algorithm processes the information and defines the amount of insulin that must be released into the body, in order to keep the patient’s sugar levels balanced within the norm. The development “closes the circle” between the sensor and the pump and frees the patient from a significant part of the daily hassle of treating diabetes, reduces fear of hypoglycemia (low sugar levels) while sleeping and significantly improves the quality of life of diabetics.

The technological solution that has been implemented in Medtronic’s insulin pump is a development that began at the Schneider Center and ended with DreaMed Diabetes, a start-up that came out of the hospital. Under the direction of Prof. Moshe Phillip and in collaboration with Dr. Revital Nimri from the Institute of Endocrinology and Diabetes at the Schneider Center, along with a team of engineers, doctors, nurses and dietitians, the team developed an algorithm that composes an individual and optimal insulin treatment plan for each patient.

In line for 50,000 type 1 diabetics: The "artificial pancreas" system has entered the health basket
Experimenting with the artificial project in its infancy. In the photo – Prof. Moshe Philip, director of the Institute of Endocrinology and Diabetes at the Schneider Center, with the children in the study.
Photo: Schneider Center spokeswoman

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Enable Notifications OK No thanks